News
GSK (LSE:GSK) Seeks European Expansion Of RSV Vaccine To Adults 18 And Older
GSK (LSE:GSK) announced that the European Medicines Agency accepted its regulatory application to expand the use of its RSV vaccine, Arexvy, to adults aged 18 and older. This announcement likely supported the company's 14% share price increase last month,
GSK said on Friday the European Medicines Agency had accepted the drugmaker’s application to expand the use of ...
The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...
The incidence of RSV across 5 respiratory virus seasons was substantial among adult patients with high-risk underlying conditions.
A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...
S hares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S.
The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback